The future of food allergy? The emergence of targeted allergy treatments
Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment
In recent years, there has been a noticeable shift in the increased public awareness of allergy-related complications both within the United Kingdom and globally. In 2010, Allergy UK estimated that at least 44% of British adults were currently suffering from at least one allergy, a statistic that only continues to rise steadily each year. In the United States, Statista reported that approximately 20% of American adults in 2017 were suffering from an allergy or food intolerance.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
Infographic: Research Partnership
Did you know that we conduct over 300 projects a year in over 70 countries and covering more than 80 therapy areas?
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.
Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter.
In addition from Q1 2019 Therapy Watch will now be tracking prescription topical treatments in both a secondary care and primary care setting providing broad visibility of the psoriasis market landscape.